a-SYN

• α-SYN-C is a blood-based biomarker detecting Calpain-1-cleaved α-synuclein fragments associated with Parkinson’s Disease (PD).
• Detects early molecular changes in PD by identifying abnormal processing and fragmentation of α-synuclein protein in neurons.
• Quantifies toxic α-synuclein fragments in serum, which are elevated in PD patients compared to healthy controls.
• Non-invasive sampling: Enables disease monitoring through a standard blood test, eliminating the need for cerebrospinal fluid or brain tissue sampling.
• Technically validated assay for precise measurement of Calpain-1-cleaved α-synuclein in human blood samples.
• Reflects pathological brain changes: Fragmented α-synuclein in blood serves as a peripheral indicator of neurodegeneration, neuronal loss, and blood-brain barrier leakage in PD.
• Enables longitudinal tracking of disease progression and response to therapy, supporting dynamic disease management.
• Facilitates early detection and intervention by providing a “window into the brain” for subclinical or early PD pathology.
• Supports research and development of targeted therapies by offering a measurable endpoint related to core disease mechanisms.
• Potential for individualized treatment by allowing stratification of patients based on molecular disease activity and therapeutic response.

α-SYN-C is a serum-based biomarker assay designed to detect specific protein fragments produced by the cleavage of α-synuclein through the action of the enzyme Calpain-1. In a healthy central nervous system, α-synuclein plays a role in supporting normal neuronal communication. When this protein undergoes abnormal processing, it can be cleaved into smaller, altered fragments by Calpain-1. These fragments are not only implicated in the disruption of normal cellular function, but their accumulation and aggregation have further downstream effects, including cellular toxicity and neurodegeneration.

A distinguishing feature of these cleaved α-synuclein fragments is their ability to cross the blood-brain barrier and enter systemic circulation. This property enables their detection in peripheral blood samples, offering a non-invasive means to access molecular information typically confined to the central nervous system. The α-SYN-C assay leverages ProteinFingerPrint Biomarker Technology™ to identify and quantify these Calpain-1-generated α-synuclein fragments with high specificity and analytical precision.

The technical validation of the α-SYN-C assay confirms its suitability for use in human blood samples, supporting accurate and reproducible detection of the biomarker. By capturing the unique “fragment fingerprint” of cleaved α-synuclein, this technology provides a reliable method for monitoring molecular processes in the nervous system through routine blood draws. Such an approach allows for dynamic assessment of neurodegenerative processes, facilitates the evaluation of therapeutic efficacy, and supports the advancement of targeted treatment strategies based on underlying molecular pathology.

Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.